<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624973</url>
  </required_header>
  <id_info>
    <org_study_id>2015/8463</org_study_id>
    <nct_id>NCT02624973</nct_id>
  </id_info>
  <brief_title>PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial</brief_title>
  <acronym>PETREMAC</acronym>
  <official_title>PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Vest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is an optimal &quot;model disease&quot; for studying personalized medicine. Breast cancer
      was the first malignancy for which a predictive factor forecasting response to therapy was
      identified nearly 50 years ago; the expression of the estrogen receptor (ER). Furthermore,
      breast cancer is by far the malignancy in which prognostic and predictive factors have been
      most extensively studied. Primary medical treatment (pre-surgical medical therapy) offers a
      unique setting to explore predictive factors due to the fact that primary breast cancers are
      easily accessible to repeated tissue sampling and evaluation of therapy response both
      clinically and radiologically. For many years, the investigators have studied predictive
      factors in primary medical treatment of breast cancer. In the present project, the
      investigators will implement a new trial concept where the current knowledge from previous
      trials with respect to predictive markers (hormone receptors, HER2; TP53, CHEK2 and RB1),
      will be combined with massive parallel sequencing (MPS). Thereby, the investigators aim to
      design the &quot;next-generation&quot; primary medical treatment where 1) therapy regimens are
      individualized based on a limited number of known predictive factors and, 2) MPS is used to
      explore additional predictive factors and their co-regulators in order to fully identify the
      mechanisms of drug sensitivity / resistance across individual tumours and pave the way for
      further personalized breast cancer therapy in the future. As for the new era of &quot;genomic
      medicine&quot;, the current trial concept will allow individual tumours to be characterized by
      their unique gene mutation / epigenetic modification profile upfront, to allocate patients to
      their optimal personalized medicine as compared to &quot;classical&quot; drug testing through phase
      II/III trials.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">June 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive and prognostic value of mutations in 300 cancer-related genes assessed in breast cancer tissue by next generation sequencing before starting neoadjuvant therapy.</measure>
    <time_frame>Ten years</time_frame>
    <description>Primary endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess genetic/epigenetic changes within the tumor tissue during therapy</measure>
    <time_frame>Before vs. 16-24 wks after treatment start. Four years: summary of all patients treated.</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The objective response rate (ORR) of personalized medicine, compared to ORR for best standard-of-care using historical data for comparison</measure>
    <time_frame>Four years</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Ki67 reduction after 2 and 5 weeks of treatment in Arm A</measure>
    <time_frame>Assessment for each patient after 2 and 5 weeks of treatment. Four years - summary of all patients in arm A.</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To estimate recurrence-free and overall survival when patients are treated with the optimal personalized treatment available as of 2015, using historical data for comparison</measure>
    <time_frame>Ten years</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the percentage of patients completing neoadjuvant treatment and completing surgery</measure>
    <time_frame>Four years</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast conserving surgery rate (potential to avoid mastectomy)</measure>
    <time_frame>Four years</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Ten years</time_frame>
    <description>Secondary endpoint</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER/PGR&gt;50% TP53 wt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER/PGR&gt;50% TP53 mutated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER/PGR&lt;50% TP53 wt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ER/PGR&lt;50% TP53 mutated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HER2+ TP53 wt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HER2+ TP53 mutated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple negative breast cancer TP53 wt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple negative breast cancer TP53 mutated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant tamoxifen + goserelin (premenopausal women)</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant letrozole (postmenopausal women)</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant docetaxel + cyclophosphamide</intervention_name>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant docetaxel</intervention_name>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant docetaxel + trastuzumab + pertuzumab</intervention_name>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab</intervention_name>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant olaparib</intervention_name>
    <arm_group_label>G</arm_group_label>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)</intervention_name>
    <arm_group_label>G</arm_group_label>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast conserving surgery or mastectomy + SNB/axillary dissection</intervention_name>
    <description>After response to neoadjuvant treatment</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
    <arm_group_label>G</arm_group_label>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Postoperative radiotherapy breast/chest wall + regional lymph nodes</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
    <arm_group_label>G</arm_group_label>
    <arm_group_label>H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant trastuzumab</intervention_name>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant letrozole (postmenopausal women)</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant tamoxifen + goserelin (premenopausal women)</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant palbociclib (if palbociclib given neoadjuvant)</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant Epirubicin+ Cyclophosphamide</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated, histologically confirmed non-inflammatory breast cancer, &gt;4 cm
             in diameter and /or metastatic ipsilateral axillary deposits for which the smallest
             diameter of the largest node &gt;2 cm by CT or ultrasound scan.

          -  WHO performance status 0-1

          -  Known tumor ER, PGR, HER2 and TP53 status.

          -  Known tumor Ki67 percentage (if ER/PGR&gt;50% and TP53 wt status).

          -  Distant metastasis not suspected. Patients will undergo radiology exams during
             screening phase, after signing the informed consent.

          -  Age &gt;18 years

          -  Patients must have clinically and/or radiographically documented measurable breast
             cancer according to RECIST.

          -  Radiology studies (CT thorax/abdomen and bone scintigraphy/bone scan) must be
             performed within 28 days prior to registration.

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial

          -  Before patient registration/randomization, written informed consent must be given
             according to national and local regulations.

          -  For arms B-H:

               -  Neutrophils &gt; 1.5 x 109/L

               -  Platelets &gt; 100 x 109/L

               -  Bilirubin &lt; 2 x upper limit normal (ULN). For patients with Gilbert´s syndrome
                  bilirubin &gt;2 x ULN is accepted if there is no evidence of biliary obstruction.

               -  Serum creatinine &lt; 1.5 x ULN

               -  ALT and Alk Phos (ALP) &lt;2.5 x ULN

               -  INR &lt; 1.5

        Exclusion Criteria:

          -  Unstable angina pectoris or heart failure

          -  Other co-morbidity that, based on the assessment of the treating physician, may
             preclude the use of chemotherapy at actual doses.

          -  Pregnant or lactating patients can not be included.

          -  Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or
             embolism does not exclude patients from inclusion, unless patient is considered unfit
             by study oncologist.

          -  Patient not able to give an informed consent or comply with study regulations as
             deemed by study investigator.

          -  Active cystitis (to be treated upfront)

          -  Active bacterial infections

          -  Urinary obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Petter Eikesdal, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant oncologist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hans Petter Eikesdal, MD PhD</last_name>
    <phone>+4755972010</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Eystein Lønning, MD PhD</last_name>
    <phone>+4755972010</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <state>Akershus</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Geisler, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jürgen Geisler, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randi Mathiesen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <state>Hordaland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Petter Eikesdal, MD PhD</last_name>
      <phone>+4755972010</phone>
    </contact>
    <contact_backup>
      <last_name>Per Eystein Lønning, MD PhD</last_name>
      <phone>+4755972010</phone>
    </contact_backup>
    <investigator>
      <last_name>Vidhi Shukla, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Petter Eikesdal, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stian Knappskog, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Turid Aas, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hildegunn Aase, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Åse Haug, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oddbjørn Straume, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sindre Molvær, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Fonna</name>
      <address>
        <city>Haugesund</city>
        <state>Rogaland</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helge Espelid, MD</last_name>
    </contact>
    <investigator>
      <last_name>Helge Espelid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Stavanger</name>
      <address>
        <city>Stavanger</city>
        <state>Rogaland</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørnar Gilje, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Bjørnar Gilje, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emil Janssen, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingvil Mjaaland, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oddmund Nordgård, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Førde</name>
      <address>
        <city>Førde</city>
        <state>Sogn Og Fjordande</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geirfinn Vagstad, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Liv Jorunn Vassbotn, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Geirfinn Vagstad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liv Jorunn Vassbotn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <state>Sør Trøndelag</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steinar Lundgren, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tone Bathen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steinar Lundgren, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helse Nord/UNN</name>
      <address>
        <city>Tromsø</city>
        <state>Troms</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Egil S Blix, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Egil S Blix, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>November 2, 2017</last_update_submitted>
  <last_update_submitted_qc>November 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neoadjuvant treatment</keyword>
  <keyword>personalized medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Tumor genomic data will be made available after publication.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

